NCT03653507 2026-04-17GLOWAstellas Pharma IncPhase 3 Active not recruiting507 enrolled 65 charts 2 FDA
NCT03093116 2026-04-03TRIDENT-1Turning Point Therapeutics, Inc.Phase 1/2 Recruiting500 enrolled 4 FDA
NCT03504397 2026-02-13SpotlightAstellas Pharma IncPhase 3 Active not recruiting565 enrolled 63 charts 2 FDA
NCT03329690 2022-03-18DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]Daiichi SankyoPhase 2 Completed233 enrolled 26 charts 2 FDA